AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 19 - (NewsRx.com & NewsRx.net) -- Investigators across the United States are currently recruiting participants for studies evaluating the safety and effectiveness of a once-yearly infusion of the Novartis drug zoledronic acid for the treatment of osteoporosis.
These studies are part of an overall clinical program known as HORIZON (health outcomes and reduced incidence with zoledronic acid once yearly).
The HORIZON program is the first to study a once-yearly dosing regimen for treating osteoporosis. HORIZON is the first program to, in a single study, prospectively evaluate both spine and hip fracture benefits as primary endpoints in women with postmenopausal osteoporosis.
The program will also evaluate a single dose of zoledronic acid given once for the treatment of Paget disease, a rare but debilitating bone disease. Worldwide, approximately 11,000 patients in 400 trial centers on four continents will be enrolled in the HORIZON program, which is one of the most comprehensive drug evaluation programs ever undertaken in the area of metabolic bone diseases.
The HORIZON pivotal fracture trial is a multinational, multicenter, double-blind, randomized, placebo-controlled, phase III study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium ...
Source: HighBeam Research, Clinical trials evaluating once-yearly zoledronic acid in...